Ciftci Rumeysa, Tas Faruk, Yasasever Ceren Tilgen, Aksit Ece, Karabulut Senem, Sen Fatma, Keskin Serkan, Kilic Leyla, Yildiz Ibrahim, Bozbey Hamza Ugur, Duranyildiz Derya, Vatansever Sezai
Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey,
Tumour Biol. 2014 Jul;35(7):6941-8. doi: 10.1007/s13277-014-1932-y. Epub 2014 Apr 17.
The transforming growth factor beta 1 (TGFB1) is a regulatory cytokine with both tumor suppressor and tumor-promoting effects in breast cancer (BC) cell lines and tissue. Data about level of circulating TGFB1 and its prognostic significance in BC patients is conflicting. The objective of this study is to determine the clinical significance of the serum TGFB1 levels in BC patients. We enrolled 96 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum TGFB1 levels were measured by ELISA method and compared with 30 healthy controls. The mean serum TGFB1 level of BC patients was significantly higher than controls (0.08 vs. 0.04 ng/ml, p < 0.001). There was no significant difference according to known disease-related clinicopathological or laboratory parameters. Serum TGFB1 level had a significant impact on overall survival in both univariate (p = 0.01) and multivariate analysis (p = 0.013). Serum TGFB1 level is elevated in BC patients and has a favorable prognostic value. However, it has no predictive role on CT response.
转化生长因子β1（TGFB1）是一种调节性细胞因子，在乳腺癌（BC）细胞系和组织中具有肿瘤抑制和肿瘤促进双重作用。关于BC患者循环中TGFB1水平及其预后意义的数据存在矛盾。本研究的目的是确定BC患者血清TGFB1水平的临床意义。我们纳入了96例经组织病理学诊断为BC且未接受化疗（CT）或放疗的女性患者。采用酶联免疫吸附测定（ELISA）法检测血清TGFB1水平，并与30名健康对照者进行比较。BC患者的血清TGFB1平均水平显著高于对照组（0.08 vs. 0.04 ng/ml，p < 0.001）。根据已知的疾病相关临床病理或实验室参数，差异无统计学意义。血清TGFB1水平在单因素分析（p = 0.01）和多因素分析（p = 0.013）中对总生存期均有显著影响。BC患者血清TGFB1水平升高，具有良好的预后价值。然而，它对CT反应无预测作用。
